Astrapharm presented a new antibacterial drug – Cefoperazone Combi

The pharmaceutical company Astrapharm launched a new antibacterial drug Cefoperazone Combi on the Ukrainian market in 2021.

The drug is used for the treatment of:

• upper and lower respiratory tract infections;
• cholecystitis, cholangitis, peritonitis and other abdominal infections;
• upper and lower urinary tract infections;
• septicemia;
• meningitis;
• skin and soft tissue infections;
• bone and joint infections;
• pelvic inflammatory disease, endometritis, gonorrhea and other reproductive tract infections.

Cefoperazone Combi is a combination of the third-generation cephalosporin – cefoperazone sodium and a beta-lactamase inhibitor – sulbactam sodium, that work synergistically. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam restores the activity of cefoperazone against strains that produce beta-lactamase.

Thereby, the advantage of Cefoperazone Combi is a reduction of the minimum concentration of the combination, which suppress a wide range of clinically significant microorganisms, by about 4 times compared with such combinations of each component separately.

General Director of Astrapharm, notes: “Nowadays the problem of antibiotic resistance in Ukraine is especially urgent. In order to meet the growing needs of the pharmaceutical market for antibiotics, in 2021 our company presented a new drug for the effective treatment of patients with bacterial infections – Cefoperazone Combi”.

Cefoperazone Combi comes in a powder for preparation of a solution for injection: 1 vial contains cefoperazone sodium equivalent to cefoperazone 1000 mg and sulbactam sodium equivalent to sulbactam 1000 mg.

The drug is dispensed on prescription only.